This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.To evaluate the safety and immunogenicity of IM administration of MVA/HIV62 at the maximum tolerated dose as series of 2-3 injections, with or without a JS7 DNA prime at the maximum tolerated dose and to review the social impacts of trial participation.
Showing the most recent 10 out of 515 publications